Personal profile
Scientific Focus
Research Group Leader for "Molecular Therapy"
- Oncogenic Pathways in Therapy Resistance
- Circulating Tumors (ct)DNA as Biomarkers
- Stem Cell Persistence and Homing
- Molecular Tumor Board
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)
- Centers: University Cancer Center Schleswig-Holstein (UCCSH)
- Centers: Center for Rare Diseases (ZSE)
DFG Research Classification Scheme
- 2.22-14 Hematology, Oncology
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Nikolas von Bubnoff is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Dupilumab treatment is not associated with changes in lymphoma risk in atopic dermatitis and other type 2 inflammatory diseases: data from a large-scale retrospective cohort study
Kridin, K., Bieber, K., Olbrich, H., von Bubnoff, D., Hernandez, G., Zirpel, H., von Bubnoff, N., Thaçi, D. & Ludwig, R. J., 2026, In: Frontiers in medicine. 12, 1702736.Research output: Journal Articles › Journal articles › Research › peer-review
-
The Significance of IL-3 Receptor beta chain for FLT3-ITD Dependent Oncogeneic Signaling in AML
von Bubnoff, N. (Principal Investigator (PI)), McInnes, C. (Principal Investigator (PI)) & Prasad Gorantla, S. (Principal Investigator (PI))
01.01.17 → 31.12.27
Project: DFG Individual Projects